Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022
Amarin Corporation plc (NASDAQ:AMRN) will host a conference call on August 3, 2022, at 8:00 a.m. ET to discuss its second quarter 2022 financial results, which will be released prior to the market opening. The call will be accessible through the Company’s investor relations website, and a replay will be available soon after. Amarin is advancing in cardiovascular disease management through clinical trials and commercial expansion, with offices in the U.S., Ireland, and Switzerland.
- Amarin is evolving rapidly in cardiovascular disease management.
- The company is committed to scientific research and clinical trials.
- None.
DUBLIN, Ireland and BRIDGEWATER, N.J., July 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s second quarter 2022 financial results on Wednesday, August 3rd, 2022 at 8:00 a.m. ET.
The conference call with management will follow the release of the Company’s second quarter 2022 financial results in the pre-market hours.
Conference Call and Webcast Information:
Access to the live call:
Go to the investor relations section of the Company's website at www.amarincorp.com
Dial in within the United States: 888-506-0062
International dial in: 973-528-0011
Access Code: 316813
Access to replay:
Dial in within the United States: 877-481-4010
International dial in: 919-882-2331
Access Code: 45865
A replay of the call will also be available through the Company's website shortly after the call.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.
Availability of Other Information About Amarin
Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor Inquiries:
Lisa DeFrancesco
Amarin Corporation plc
IR@amarincorp.com (investor inquiries)
Media Inquiries:
Mark Marmur
Amarin Corporation plc
PR@amarincorp.com (media inquiries)
FAQ
When will Amarin announce its Q2 2022 financial results?
How can I participate in Amarin's conference call?
Where can I find more information about Amarin's financial performance?
